NO974727L - Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation - Google Patents

Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation

Info

Publication number
NO974727L
NO974727L NO974727A NO974727A NO974727L NO 974727 L NO974727 L NO 974727L NO 974727 A NO974727 A NO 974727A NO 974727 A NO974727 A NO 974727A NO 974727 L NO974727 L NO 974727L
Authority
NO
Norway
Prior art keywords
compositions
immunogenic
oligosaccharide
antigen
preparation
Prior art date
Application number
NO974727A
Other languages
Norwegian (no)
Other versions
NO974727D0 (en
Inventor
Andrew J Malcolm
Original Assignee
Alberta Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/482,626 external-priority patent/US5695768A/en
Priority claimed from US08/477,497 external-priority patent/US5866132A/en
Priority claimed from CA002153730A external-priority patent/CA2153730A1/en
Priority claimed from CA002153733A external-priority patent/CA2153733A1/en
Application filed by Alberta Res Council filed Critical Alberta Res Council
Publication of NO974727D0 publication Critical patent/NO974727D0/en
Publication of NO974727L publication Critical patent/NO974727L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er beskrevet immunogene oligosakkaridsammensetninger og fremgangsmåter for fremstilling av disse og anvendelser derav. Sammensetningene omfatter spesielt oligosakkarider kovalentlig koblet til bærerprotein, hvori det resulterende konjugatet er blitt vist å inneholde spesifikke immunogene epitoper og utløser en beskyttende immunogen respons. Det er også tilveiebrakt sammensetninger som omfatter et oligosakkarid av S. pneumoniae serotype 8 nyttig for stimulering av en immunrespons mot et antigen, fremgangsmåte for tilveiebringing av beskyttende immunisering mot et bakterielt patogen ved anvendelse av disse sammensetningene, fremgangsmåte for å forøke en immunogen respons mot et antigen ved administrering av disse S. pneumoniae serotype 8 oligosakkarid sammensetningene sammen med antigenet, og fremgangsmåte for fremstilling av immunstimulatoriske sammensetninger beskrevet ovenfor.Immunogenic oligosaccharide compositions and methods for their preparation and applications are disclosed. In particular, the compositions comprise oligosaccharides covalently linked to carrier protein, wherein the resulting conjugate has been shown to contain specific immunogenic epitopes and triggers a protective immunogenic response. Compositions comprising an oligosaccharide of S. pneumoniae serotype 8 are also useful for stimulating an immune response to an antigen, a method of providing protective immunization against a bacterial pathogen using these compositions, a method of enhancing an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions together with the antigen, and method of preparing immunostimulatory compositions described above.

NO974727A 1995-06-07 1997-10-13 Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation NO974727L (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/482,626 US5695768A (en) 1995-06-07 1995-06-07 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US08/477,497 US5866132A (en) 1995-06-07 1995-06-07 Immunogenic oligosaccharide compositions
CA002153730A CA2153730A1 (en) 1995-07-12 1995-07-12 Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides
CA002153733A CA2153733A1 (en) 1995-07-12 1995-07-12 Immunogenic oligosaccharide compositions
PCT/CA1996/000387 WO1996040225A1 (en) 1995-06-07 1996-06-06 Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them

Publications (2)

Publication Number Publication Date
NO974727D0 NO974727D0 (en) 1997-10-13
NO974727L true NO974727L (en) 1997-12-08

Family

ID=27427244

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974727A NO974727L (en) 1995-06-07 1997-10-13 Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation

Country Status (10)

Country Link
EP (1) EP0831894A1 (en)
JP (1) JPH11506110A (en)
KR (1) KR19990007777A (en)
AU (1) AU725279B2 (en)
CZ (1) CZ327897A3 (en)
IL (1) IL121585A0 (en)
MX (1) MX9707944A (en)
NO (1) NO974727L (en)
NZ (1) NZ309713A (en)
WO (1) WO1996040225A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69708318T3 (en) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville NEISSERIA MENINGITIDIS SEROGRUPPE B GLYCOCONJUGATES AND METHOD FOR THEIR USE
BR9811475A (en) * 1997-07-17 2000-08-15 North American Vaccine Inc Immunogenic conjugates comprising a group b meningococcal porin and an h polysaccharide. influenzae
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU760669B2 (en) * 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
IL153558A0 (en) * 2000-06-20 2003-07-06 Shire Biochem Inc Streptococcus antigens
EP3461496B1 (en) * 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
AU2015208821B2 (en) * 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3000820A1 (en) * 2014-09-26 2016-03-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against Streptococcus pneumoniae serotype 8
CA2961694C (en) * 2014-09-26 2022-11-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Vaccines against streptococcus pneumoniae serotype 8
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CA3074714A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
AU2019215216A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019215212A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
US11951162B2 (en) 2018-04-18 2024-04-09 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
EP3893926A1 (en) * 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CN113607939A (en) * 2021-08-05 2021-11-05 艾美探索者生命科学研发有限公司 Method for measuring adsorption rate of various combined stock solutions of pneumococcal polysaccharide combined vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187753B (en) * 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE137981T1 (en) * 1990-12-18 1996-06-15 Univ Washington DIALYSAT PRODUCTION SYSTEM WITH PILLS
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae

Also Published As

Publication number Publication date
EP0831894A1 (en) 1998-04-01
WO1996040225A1 (en) 1996-12-19
AU725279B2 (en) 2000-10-12
MX9707944A (en) 1998-06-30
KR19990007777A (en) 1999-01-25
NO974727D0 (en) 1997-10-13
CZ327897A3 (en) 1998-02-18
AU5994496A (en) 1996-12-30
NZ309713A (en) 1999-11-29
JPH11506110A (en) 1999-06-02
IL121585A0 (en) 1998-02-08

Similar Documents

Publication Publication Date Title
NO974727L (en) Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation
Chu et al. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates
Schneerson et al. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates
EP0789587B2 (en) Combined meningitis vaccine
Devi et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity
AU8483391A (en) Improved oligosaccharide conjugate vaccines
Lagergard et al. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid
CA2188284C (en) Group a streptococcal polysaccharide immunogenic compositions and methods
AU3065489A (en) T-cell epitope as carriers molecule for conjugate vaccines
CA2142981A1 (en) Vaccines against group c neisseria meningitidis
JPH07506811A (en) Dual carrier immunogenic constructs
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
Wetherell Jr et al. Antigens of Streptococcus mutans: characterization of a polysaccharide antigen from walls of strain GS-5
Pawlowski et al. Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
Takada et al. Serological characterization of Streptococcus mutans serotype polysaccharide g and its different molecular weight forms
Lieberman et al. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions
Pier et al. Isolation, structure, and immunogenicity of Pseudomonas aeruginosa immunotype 4 high-molecular-weight polysaccharide
NO913131L (en) IMMUNOGENIC CONJUGATES OF NON-TOXIC OLIGOSACCHARIDE FROM TABLE TELL PERTUSSIS LIPOOLYSACCHARIDE.
Jackson et al. Immune Responses to Lipoteichoic Acid: Comparison of Antibody Responses in Rabbits and Mice: Part II
RU2001107132A (en) IMMUNOGENIC BETA-PROPIONAMIDE-BINDED POLYSACCHARIDE CONJUGATE USED AS A VACCINE RECEIVED WITH N-ACRYLOILED POLYSACCHARID
Szu et al. Vaccines for prevention of enteric bacterial infections caused by Salmonellae
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application